Gene Editing in Human Embryos Leaps ForwardHere’s the Science – Singularity Hub

Imagine walking down the street with a ticking time bomb in your chest, never knowing when your heart may explode.

Or going through five decades of life, having kids, and always wondering when your mind will finally slip away from you. Or worse yet, knowing that one day the same will inevitably happen to your children and your grandchildren.

If there were a curea way to irreversibly correct the faulty biology in yourself and your offspringwould you do it? And knowing that there might be risks, would you be comfortable making that decision for generations to follow?

Last week, a remarkable study published in Nature brought these and other questions back into public discourse. For the first time, an international team led by US scientists used CRISPR, a genetic editing tool, to correct a mutation that leads to heart failure in viable human embryos.

This isnt the first time scientists have tinkered with human embryos. But it is the first that shows that certain off-target effectspreviously thought immensely challengingcan be dealt with in a relatively straightforward way.

In other words, the new technology just brought us one step closer to correcting genetic deficits in humans. And what can be used to right a disease can also be used to enhance a healthy babyartificially altering their intelligence or physical appearance.

To be clear, this study is a long way off from the complicated changes required to make designer babies. This isnt Brave New World or Gattaca.

This is for [the] sake of saving children from horrible diseases, says lead author Dr. Shoukhrat Mitalipov at the Oregon Health and Science University, who previously worked on Dolly the sheep and three-parent babies.

And with this milestone, says Dr. George Church at Harvard University, were one step closer.

The human body runs on the tens of thousands of genes that form the code of life. Sometimes, just a single faulty gene can have devastating consequences, such as Huntingtons disease or hypertrophic cardiomyopathya condition that often leads to heart failure.

For decades, scientists have tried hacking lifes code to cure these genetic diseases at the DNA level. The process seems straightforward: like programmers decoding a bug, scientists would read through the bodys encyclopedia of genes, identify the faulty member, cut and paste the correct code into the original spotand voil, fixed!

The promise of genetic cures seemed easily within reach when a technology called CRISPR came onto the scene in 2012. CRISPR itself isnt a cure. Rather, its a pair of molecular scissors that scientists can direct to almost any point on the human genome and make a precise cut.

The cut triggers a cell to activate a DNA repair program. Almost all cells do this, but embryos go about it slightly differently. If provided with a normal copy of the gene, embryos will use the blueprint gene to reconstruct the broken piece, essentially overwriting the mistaken code. In theory, this leads to fewer mistakes than a normal cells stitch it up repair program, which doesnt use templates.

In practice, however, embryonic DNAs been hard to hack. Just two years ago, Chinese scientists reported giving up on correcting a genetic abnormality in human embryos due to off-target effects, saying that the CRISPR-based technology was too immature.

And for good reason. The safety and ethical barriers are enormous when editing embryosso-called germline editing. The reason is this: after sperm meets egg, the resulting single cell will develop into a persons entire body. This means that any changes to an embryo will (in theory) be present in every single cell in the grown human, including reproductive cells.

In other words, any changes to the embryo will not only affect the person it will become, but also his or her children, and their children and so on. If any unwanted mutation sneaks in during the procedure, the harm is multi-generational.

Then theres the problem of mosaicism. Oftentimes, an edited embryo can lead to a mosaic of genotypes in the resulting cellssome fixed, some not, and the individual still ends up with the disease.

The new study tackles both problems head-on.

Mitalipovs team decided to focus on hypertrophic cardiomyopathy, an inherited disease due to a gene called MYBPC3. People with the condition have two copies of the gene: one normal, one faulty. This means they have a 50-50 chance of passing the condition to their children.

Because the embryo already contains a normal copy of MYBPC3, explain the authors, it already has a blueprint the cell could use to repair the abnormal one. The team recruited a dozen healthy egg donors and one sperm donor that carried the faulty MYBPC3.

Normally, scientists encode all CRISPR components into an external bit of DNA called a plasmid, put that into a cell and rely on the cell to make the necessary proteins and molecules. Mitalipovs team took a more unusual route: using a tiny syringe, they directly injected the CRISPR machinery into either a fertilized embryo or into the egg cell right before fertilization.

In the first case, the CRISPR machinery sticks around for a long time. This increases the chance that it might go rogue and snip parts of the DNA it wasnt designed to cut.

By directly injecting the components, the CRISPR scissors are chewed up by the recipient cell after they do their work: less random snipping, more precision.

The tactic worked. When the team analyzed the resulting embryos at the four- or eight-cell stage, they found 72 percent contained only normal copies of the MYBPC3 gene, compared to roughly 50 percent found in non-edited controls.

Even though the yield of wild type/wild type embryos is still higher, its not 100 percent. We have room to improve, says Mitalipov.

Heres the kicker: using a variety of modern genetic sequencing techniques, the team scrutinized the embryos genomes for off-target effects. They couldnt find any. For all intents and purposes, the edited embryos looked completely healthy.

This doesnt necessarily mean the team avoided all unexpected mutations. It just means any genetic deletions or inserts didnt affect the embryos normal development.

Thats not all. The team also surprisingly found a way to minimize mosaicism. The key is to inject CRISPR components into the egg at the same time as they pumped in the sperm to fertilize it. This is much earlier in the developmental stage than anyone had previously attempted.

It worked. Out of the 58 treated eggs fertilized with the mutant sperm, 42 contained two normal copies of MYBPC3. Only one became a mosaic. In contrast, CRISPRing a fertilized embryo led to 13 out of 54 mosaics.

It makes previous work look pretty amateurish in terms of mosaicism and in terms of off-target effects, says Church.

Surprisingly, rather than bolstering a designer baby future, the study may have inadvertently doused a cold case of biological reality on the sci-fi idea.

Dr. Robin Lovell-Badge, a developmental biologist at the Francis Crick Institute in London, pointed out that the most unexpected result of the study is how the embryo chose to repair the gene.

In one experiment, the team tried introducing an artificial template of MYBPC3 in addition to the normal copy already present in the cell (from the healthy moms). But the cells completely ignored the researchers template, instead exclusively opting to use the maternal MYBPC3 to repair the mutation.

This suggests that you couldnt add anything that wasnt already there, says Lovell-Badge.

To Mitalipov, the crux of the conversation should be solidly based in therapy. My goal has always been to treat genetic diseases that have no cures, to save children, he says.

And there are still a lot of kinks that need ironing out before CRISPR could enter clinics. For one, scientists still hope to increase precision and accuracy. For another, IVF clinics already have solid screening protocols in place to weed out genetic abnormalities before implantation. While CRISPR can, in theory, boost the number of healthy embryos, it would have to work better to justify the cost.

To Dr. Richard Hynes, a cancer researcher at MIT who co-led a national committee that recently published a new guideline for editing embryos, the study is a big breakthrough.

What our report said was, once the technical hurdles are cleared, then there will be societal issues that have to be considered and discussions that are going to have to happen. Nows the time, he says.

Image Credit: University of Michigan via Flickr

Read this article:
Gene Editing in Human Embryos Leaps ForwardHere's the Science - Singularity Hub

Global Cancer Biological Therapy Market 2017 Size, Development Status, Type and Application, Segmentation … – Digital Journal

""Cancer Biological Therapy Market""

WiseGuyReports.com adds Cancer Biological Therapy Market 2017 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023reports to its database.

Cancer Biological Therapy Market:

Executive Summary

Biological therapy treatment is done with the help of living organisms, parts of living organisms or laboratory manufactured version of such content. There are various types of biological therapies, which inhibit specific molecules involved in development and growth of cancer tumor. Such therapies known as; cancer targeted therapies.

The global cancer biological therapy market is expected to reach USD 82,276.8 million by 2023 at a CAGR of 4.7% during the forecasted period.

The global cancer biological therapy market is segmented on the basis of phases, types, end users and regions. On the basis of phases, the market is segmented into phase I, phase II and phase III. In stage I & II the real impact of these therapies is seen and giving a success rate of 35% in Phase 1 and 20% in Phase II. The success rate of phase I is 35%.

On the basis on types, the global cancer biological therapy market is segmented into monoclonal antibodies, cancer growth blockers, interferons, interleukins, gene therapy, targeted drug delivery, colony stimulating factor, cancer vaccines and others. Monoclonal antibodies accounted for the largest market share of the global cancer biological therapy market. Colony stimulating factor is the fastest growing market at a CAGR of 5.2% during the forecasted period.

On the basis on end users, hospitals & clinics dominates the global cancer biological therapy market. Registering USD 26,790.6 million in 2016 and expected to reach at USD 38,471.9 million by 2023 at the rate of 4.4 % from 2016-2023.

On the basis of regions, the market is segmented into North America, Europe, Asia-Pacific and the Middle East & Africa. North America has the dominating market for cancer biological therapy. The cancer biological therapy market for North America is estimated at USD 19,481.2 million in 2016 and expected to reach by USD 29,516.9 million by 2023 at a fastest CAGR of 5.10%.

Request Sample Report @ https://www.wiseguyreports.com/sample-request/1793685-global-cancer-biological-therapy-analysis-forecast-2016-to-2023

Key Players

The leading market players in the global cancer biological therapy market include Merck Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Amgen Inc., Bristol-Myers Squibb, Celgene, ELI Lilly and Company, EnGeneIC, and Pfizer

Study objectives

Target Audience

For further information on this report, visit -https://www.wiseguyreports.com/enquiry/1793685-global-cancer-biological-therapy-analysis-forecast-2016-to-2023

Key Findings

The reports also covers regional analysis

o US

o Canada

o Germany

o France

o U.K.

o Italy

o Spain

o Rest of Europe

o Japan

o China

o India

o Republic of Korea

o Rest of Asia-Pacific

o Middle East

o Africa

Continued

Buy this Report@https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1793685

Media Contact Company Name: Wiseguyreports.com Contact Person: Norah Trent Email: sales@wiseguyreports.com Phone: +1 646 845 9349, +44 208 133 9349 City: Pune State: Maharashtra Country: India Website: http://www.wiseguyreports.com

Here is the original post:
Global Cancer Biological Therapy Market 2017 Size, Development Status, Type and Application, Segmentation ... - Digital Journal

Traditional Therapy Clinics Ltd (TTC.AX) Money Flow Index Levels in Focus – Stock Daily Review

Traditional Therapy Clinics Ltd (TTC.AX) shares have seen theMoney Flow Indicator drop below 30, potentially spelling a near-term reversal if it crosses below the 20line. The Money Flow Indicatoris a unique indicator that combines momentum and volume with an RSI formula. Because of its incorporation of volume, the MFI is better suited to identify potential reversals using both overbought/oversold levels and bullish/bearish divergences. As with all indicators, the MFI should not be used by itself. A pure momentum oscillator, such as RSI, or pattern analysis can be combined with the MFI to increase signal accuracy.

The MFI was created by Gene Quong and Avrum Soudack and they believed a reading above 70-80 would signify Overbought territory where a reading below 20-10 would indicate that the conditions wereindicative of an Oversold price level.

Investors might be interested in taking a closer look at additional stock technical levels. After a recent check, Traditional Therapy Clinics Ltd (TTC.AX) has a 14-day ATR of 0.02. The average true range indicator was created by J. Welles Wilder in order to measure volatility. The ATR may help traders to determine the strength of a breakout or reversal in price. It is important to mention that the ATR was not designed to calculate price direction or to predict future prices.

Currently, the 14-day ADX for Traditional Therapy Clinics Ltd (TTC.AX) is sitting at 23.62. Generally speaking, an ADX value from 0-25 would indicate an absent or weak trend. A value of 25-50 would support a strong trend. A value of 50-75 would identify a very strong trend, and a value of 75-100 would lead to an extremely strong trend. ADX is used to gauge trend strength but not trend direction. Traders often add the Plus Directional Indicator (+DI) and Minus Directional Indicator (-DI) to identify the direction of a trend.

Checking in on some other technical levels, the 14-day RSI is currently at 32.37, the 7-day stands at 23.25, and the 3-day is sitting at 9.65. Many investors look to the Relative Strength Index (RSI) reading of a particular stock to help identify overbought/oversold conditions. The RSI was developed by J. Welles Wilder in the late 1970s. Wilder laid out the foundation for future technical analysts to further investigate the RSI and its relationship to underlying price movements. Since its inception, RSI has remained very popular with traders and investors. Other technical analysts have built upon the work of Wilder. The 14-day RSI is still a widely popular choice among technical stock analysts.

Investors may be watching other technical indicators such as the Williams Percent Range or Williams %R. The Williams %R is a momentum indicator that helps measure oversold and overbought levels. This indicator compares the closing price of a stock in relation to the highs and lows over a certain time period. A common look back period is 14 days. Traditional Therapy Clinics Ltd (TTC.AX)s Williams %R presently stands at -100.00. The Williams %R oscillates in a range from 0 to -100. A reading between 0 and -20 would indicate an overbought situation. A reading from -80 to -100 would indicate an oversold situation.

Taking a closer look from a technical standpoint, Traditional Therapy Clinics Ltd (TTC.AX) presently has a 14-day Commodity Channel Index (CCI) of -229.42. Typically, the CCI oscillates above and below a zero line. Normal oscillations tend to stay in the range of -100 to +100. A CCI reading of +100 may represent overbought conditions, while readings near -100 may indicate oversold territory. Although the CCI indicator was developed for commodities, it has become a popular tool for equity evaluation as well.

Read this article:
Traditional Therapy Clinics Ltd (TTC.AX) Money Flow Index Levels in Focus - Stock Daily Review

Vitamin C injections could play a role in treating blood cancers – NHS Choices

Monday August 21 2017

AML is an aggressive cancer of the white blood cells

"Super-strength vitamin C doses could be a way to fight leukaemia," the Mail Online reports. Research in mice found vitamin C could help combat the effect of a mutated gene that can cause uncontrollable stem cell growth and trigger the onset ofacute myeloid leukaemia (AML).

AML is an aggressive cancer of the white blood cells that usually affects older people. It is thought that some cases of AML are caused by a mutation in the Tet Methylcytosine Dixoygenase 2 (TET2) gene. This gene helps mature stem cells into specialised white blood cells. The mutation can lead to uncontrollable growth of cancerous cells leading to AML.

The researchers used mice to explore whether use of vitamin C could restore the TET2 gene to working order and help slow the progression of leukaemia.

The study found that using high doses of vitamin C intravenously did in fact suppress the growth of leukaemia cancer stem cells in the mice.

Although this does pave the way for future therapeutic approaches, this study was very early stage research in mice, and therefore would require further investigation and trials in humans before any treatment based on the findings could beoffered to patients.

Also, the dose used was far higher relative to weight, than would be safe in humans. It would be the equivalent of a human taking 300g of vitamin C,which would mean eating more than 5,000 oranges. So scientists would also have to find a way to lower the dose while achieving the same beneficial effect.

The study was carried out by researchers from several institutions, including New York University and Monash University in Australia. It was funded by numerous institutions such as the US NIH, the Leukaemia & Lymphoma Society and the Chemotherapy Foundation.

The study was published in thepeer-reviewed scientific journal Cell.

The UK media's coverage on this topic was generally accurate, highlighting that this is not a treatment that would be used by itself, but instead in combination with other approaches, such as chemotherapy.

This was an animal study which investigated whether treatment with vitamin C could restore function of Tet Methylcytosine Dixoygenase 2 (TET2) and therefore block the progression of leukaemia in mice.

TET2 is one of the most frequent mutations in diseases and cancers of the blood such as leukaemia. The TET2 gene encodes a protein involved in the production of bone marrow and blood cells. As a result, defects and mutations of TET2 can negatively affect the process which causes stem cells to turn into blood cells. In turn, this can promote the progression of leukaemia.

The researchers wanted to explore the role of TET2 deficiency in the maintenance of leukaemia stem cells.

The researchers further investigated whether vitamin C could be useful in the treatment of blood cancers. This is because treatment with vitamin C has previously been tested in solid tumours (tumours located in one part of the body, such as the lungs) and in some cases, been found to result in better patient outcomes.

Animal studies such as this are useful for early stage research. Butwhile there are many genetic similarities between mice and humans, we aren't identical. Therefore further testing is required in people to be sure of the effect of any treatment.

The researchers implanted leukaemia stem cells, extracted from humans, into mice and also used mice that were deficient in TET2.

To determine the effects of mutations that could reduce TET2 function, the mice were genetically engineered so that the TET2 gene could be switched on or off.

High doses of vitamin C were then administered intravenously to the mice and the function of TET2 and cell behaviour was studied.

The researchers also tested the use of vitamin C alongside PARP inhibitors. PARP inhibitors are a class of chemotherapy drugs that can help repair damaged DNA.

The researchers found that when the function of TET2 was switched off in the mice, abnormal stem cell behaviour occurred. This was reversed however once the function of TET2 was switched back on, confirming that loss of function of TET2 would in fact play a role in the formation of cancerous stem cells in diseases such as leukaemia.

In the TET2 deficient mice, the effects of TET2 deficiency were reversed following having intravenous vitamin C administered. The vitamin C treatment also induced the stem cells to mature and suppressed the growth of leukaemia cancer stem cells in the mice implanted with cell lines from human patients with leukaemia.

The researchers also found that following vitamin C treatment, the leukaemia cell lines were more sensitive to treatment with PARP inhibitors.

The researchers concluded: "We have found that targeted restoration of Tet2 is sufficient to block aberrant self-renewal of pre-leukemic stem cells. Similarly, vitamin C, by enhancing the activity of TET family dioxygenases, acts as a pharmacologic mimic of Tet2 restoration. Moreover, genetic or pharmacological restoration of TET activity confers an emergent vulnerability in leukemia cells, rendering them more sensitive to PARP inhibitors. Together, these results suggest new therapeutic strategies for clonal hematopoiesis, MDS and AML."

This mouse study explored whether treatment with vitamin C could restore function of TET2 and therefore block the progression of blood cancers like leukaemia.

It found that using high doses of vitamin C intravenously did in fact suppress the growth of leukaemia cancer stem cells in the mice implanted with cell lines from human patients with leukaemia.

It also reported that using vitamin C alongside existing treatment with PARP inhibitors helped reduce the progressions of the disease.

The researchers suggest that in the future, vitamin C could be used alongside chemotherapy and other conventional treatment forms.

This is exciting early stage research, with potential to pave the way for future treatment options for leukaemia and other blood cancers.

One of the challenges of treating acute myeloid leukaemia is that patients are usually older so it is often not safe to use very aggressive forms of chemotherapy. Hopefully vitamin C, or a similar substance, could help enhance the effects of milder forms of chemotherapy.

However, because this was an animal study, these results would need further investigation and have to undergo clinical trials in humans before new treatments based on these findings could be offered to patients.

It is far too soon to start taking high doses of vitamin C on the basis of this research, especially as large amounts of the vitamin (more than 1g per day per person) can cause stomach upsets. Some mice in this study received 100 milligrams, which would be equivalent to humans receiving 300g of pure vitamin C.

From what we know about AML, it would seem that the one way to reduce your chances of developing this cancer is to quit smoking.

See original here:
Vitamin C injections could play a role in treating blood cancers - NHS Choices

STONE: Certain medical practices can prey on false hopes – Odessa American

Its human nature to want a quick fix in resolving issues or problems. Getting maximum results with minimal effort certainly has its appeal. From Thigh Masters and Bowflexes to The Clapper and Ginsu knives, the promise for rapid results and convenience can draw consumers in like the late-night glow of the TV infomercials selling these items.

But, lets be honest, these examples may have yield their desired results, but most products end up being a total disappointment and waste of money. This is also the case with certain medical procedures or therapies claiming to fix certain ailments or chronic conditions. As a patient-consumer, its important to do your research and not let emotions or false hopes guide you into making a potentially expensive or even risky decision involving your health.

One item in general, stem cell therapy, has been getting quite a bit of attention of late. Many may ask, what are stem cells? Stem cells are cells that have the potential to develop into many different types of cells. Think of them as a blank canvas which can divide and become specialized cells within the body such as blood, liver, or muscle cells. Stem cell therapy acts by introducing these cells into some areas of the body, to which the stem cells can divide regularly to regenerate and/or repair existing tissue. Stem cell therapy has long been used by physicians to treat certain types of cancers, such as leukemia and lymphoma as well as treating some bone, skin, and corneal eye injuries. But, while stem cells continue to be studied as potential treatments for other ailments and conditions, there are very few of these treatments currently that have been proven to be effectivelet alone safe.

With catchy, even gimmicky, tag lines like make me walk again, feel young again, or no surgery, no side effects, clinics (both in the United States and outside of it) are offering stem cell therapy to treat a laundry list of conditions. The problem with it is patient testimonials and gimmicky marketing techniques can be misleading. One resource beneficial in better understanding stem cell therapies is the International Society for Stem Cell Research (ISSCR). It represents academia and industry on a broad range of issues that affect the well-being of patients and their families, and strives to educate the public and government regulators on the basic principles of stem cell science and the realistic potential for new medical treatments and cures.

According to the ISSCR, when there is no existing or effective treatment for a disease or condition it is easy to understand why you may feel there is nothing to lose from trying something new, even if it isnt proven. Unfortunately, most of the unproven stem cell treatments for sale throughout the world carry very little promise of actual benefit and very real risks.

Many stem cell therapy clinics may offer the use of a patients own cells, also known an autologous transplant. In theory, your immune system would not attack your own cells if they were used in a transplant. However, the processes by which the cells were acquired, grown and then reintroduced into the body would carry risks. Here are just a few known risks of autologous stem cell treatments:

If you have thought about or are considering stem cell therapy, first get the guidance of your primary healthcare provider. They can help guide you in obtaining the right literature and evidence in help making the right decision for the safest and most effective treatments available. Snake oil salesmen exist in every industryincluding those wearing white lab coats. Choose your care wisely.

Continued here:
STONE: Certain medical practices can prey on false hopes - Odessa American

Spanish town struggles to square growth of extremist cell – Medicine Hat News

By Lori Hinnant, Alex Oller And Joseph Wilson, The Associated Press on August 20, 2017.

RIPOLL, Spain They were brothers and boyhood friends from a town with no unfamiliar faces. They were linked by Moroccan roots and equally tied by their upbringings in Ripoll, an ancient hub in the Catalan foothills known for its monastery and passageways dotted with cafes and kebab shops.

But most recently, police believe, the young men were drawn together by an imam and an alleged plot to murder on a massive scale an extraordinary secret for 12 people to keep for months on end.

In the suspected extremist cells final days, the group accumulated more than 100 gas canisters, blew up a house in a botched effort to make bombs, drove a van through Barcelonas storied Las Ramblas promenade, and attacked beachside tourists, Spanish authorities said.

The Islamic State group claimed responsibility for the attacks that killed at least 14 people and left scores wounded. Five of the dozen were shot dead by police.

Now, Ripoll is cut off by police roadblocks as the search for an alleged cell member thought to still be on the run continues. Families and friends in the town are torn between horror at the bloodshed and grief for the children they thought they knew.

We dont know whether to cry and mourn them or what to do, said Wafa Marsi, who knew the attackers and stood with their weeping mothers on Saturday as they clustered in small groups in the town square. They have killed 13 or 14 people and wounded a hundred, and we dont know what to do.

What the families finally did, after fiercely debating the issue, was denounce the attack, some holding up homemade signs reading Not in our name.

Police have identified 12 members of the cell, but three remained unaccounted for Sunday. Two are believed to have been killed when the house where the plot was hatched exploded Wednesday, Catalan police official Josep Lluis Trapero told reporters Sunday.

Complicating the manhunt for the suspected fugitive and any other possible accomplices, though, was the fact that police so far have been unable to pinpoint who remained at large. The explosion in Alcanar, 300 kilometres (186 miles) south of Ripoll, nearly obliterated the bomb makers along with the house. A police official has said the imam, Abdelbaki Es Satty, is thought to be one of them.

Trapero declined to confirm that Younes Abouyaaquoub, a 22-year-old Moroccan, was the one at large and the suspected driver of the van that plowed down the Las Ramblas promenade Thursday, killing 13 people and injuring 120. Another attack hours later killed one person and injured others Cambrils, a seaside town south of the city.

We are working in that line, Trapero said. But he added: We dont know where he is.

Another police official did confirm that three vans tied to the investigation were rented with Abouyaaquoubs credit card: The one used in the Las Ramblas carnage, another found in Ripoll, where all the main attack suspects lived, and a third found in Vic, on the road between the two.

Police are investigating whether a man found stabbed to death inside a car in Barcelona may have been killed by an attacker as well.

Police believe the cell members had planned to fill the vans with explosives and create a massive attack in the Catalan capital. Trapero confirmed that more than 100 tanks of butane gas were found at the Alcanar house that exploded, as well as ingredients of the explosive TATP, which was used by the Islamic State group in attacks in Paris and Brussels.

Our thesis is that the group had planned one or more attacks with explosives in the city of Barcelona, he said. The plot was foiled when the house in Alcanar blew up Wednesday night.

None of the 12 had any known history of violent extremism, Spanish police have said.

Trapero confirmed the imam was part of the investigation, but said police had no solid evidence that he was responsible for radicalizing the young men in the cell. Es Satty in June abruptly quit working at a mosque in Ripoll and has not been seen since.

Dont criminalize the mosques because the overwhelming majority of them are places of worship. They are places where people pray, Trapero said. In fact, even though there is an imam implicated in the group, it doesnt mean that the mosque is where they were radicalized.

One woman who was close to multiple attackers and who heard Es Sattys sermons said the imam repeatedly preached about jihad and killing infidels. She spoke on condition of anonymity, fearing she would be attacked for speaking out.

I feel like I could have done something. I feel a little bit guilty now, she said. Everybody knew it. It was an open secret. But I cant say it because these people are dangerous and they could come after me. I dont trust anybody now.

Es Sattys former mosque denounced the deadly attacks, but denied Es Satty was anything other than a normal imam.

Hammou Minaj, secretary of the mosque who knew the attackers as well, described Es Satty as an easygoing preacher.

Its hard to get an imam. When you get one, youre always happy Minaj said.

The mosque is on a main artery in Ripoll named Progress, occupying an unmarked corner storefront. The Muslim community took the space when it outgrew the towns other mosque, which held just 40 worshippers. Es Satty preached first at the smaller space and eventually lost his job in late 2015 for reasons that the president, Ali Yassine, did not specify.

Es Satty then left to look for work as an imam in Belgium from January to March 2016, according to Hans Bonte, mayor of the Belgian city of Vilvoorde.

Vilvoorde is known as a hub for Islamic State recruiting and jihadi activity. Police there contacted the Catalan department of justice and were told Es Satty had no links to extremist violence.

With what we know today, this is remarkable and an eye-opener for everybody, Bonte told De Morgen newspaper.

But Catalonia itself has become increasingly known as a centre of extremism and for tensions within the Muslim community on how to handle it. Nearly one-third of the arrests in Spain for alleged links to the Islamic State group were made in Catalonia, according to an analysis last year by Fernano Reinares of the Royal Institute Elcano, a Spanish think-tank founded by the king.

When Es Satty returned to Ripoll, he again landed a job as imam this time at the new mosque. But at the beginning of the summer, Es Satty announced he wanted a three-month vacation in Morocco and the mosque let him go. His apartment was empty on Saturday.

Ripoll resident Marsi, as well others who spoke with the AP on condition of anonymity, admitted tensions brewed at times between the two mosques, although Marsi pointed out that the differences were not over religious content.

I cant vouch for anybody else, but I can guarantee one hundred per cent that there was zero radicalization in either mosque. If the Imam had said something about jihad, the people of Ripoll would have ousted him. The women, in particular, are raging right now, Marsi emphasized.

The size of the cell and the close family connections among the attack suspects recalled the November 2015 attacks in Paris, where Islamic State adherents struck the national stadium, a concert hall and bars and restaurants nearly simultaneously, leaving 130 people dead.

Catalan authorities have not released the names of those killed, but Spanish media have reported widely that at least three sets of brothers were among the cells alleged members.

Brothers radicalizing together are a common theme among extremists. They share unbreakable bonds, an ability to keep secrets, and an airtight communication channel. A pair of brothers carried out suicide bombings in March 2016 in Brussels. Two brothers gunned down the staff members of satirical newspaper Charlie Hebdo in Paris in January 2015. Dzhokhar and Tamerlan Tsarnaev, who bombed the Boston Marathon in 2013, were brothers originally from Chechnya.

On Sunday, many in Ripoll said they didnt see themselves in either the young men who had once seemed familiar or the imam now implicated in the investigation

Those people that heard him talk about jihad and didnt say anything, are they happy now? Why didnt they stop him? Hassan Azzidi, who was holding a sign that read Not in the name of Islam, said.

He added: We are taught not to kill animals for sport, let alone humans.

___

Wilson contributed from Barcelona. Angela Charlton in Paris; Nicole Winfield in Rome; Alex Oller and Mystyslav Chernov in Ripoll, Spain; and Oleg Cetinic in Alcanar, Spain contributed.

You must be logged in to post a comment.

See more here:
Spanish town struggles to square growth of extremist cell - Medicine Hat News

New Study Reveals Stem Cells from Young Hearts May Help Reverse the Aging Process – Futurism

In BriefA new study from the Cedars-Sinai Heart Institute reveals thatstem cells taken from younger rats provided older rats withyouthful vigor when injected into their hearts. After a month, therats ran longer, and regrew hair faster. To Be Young Again

Old hearts may find new life, according to a new study, which shows that stem cells taken from younger hearts can be used to reverse the aging process. This could potentially cause older hearts to act and perform like younger ones.Click to View Full Infographic

The study, conducted by the Cedars-Sinai Heart Institute and published by the European Heart Journal, set out to observe the effects of cardiac stem cells on various aspects of the heart, including its function and structure. Prior applications of Cardiosphere-derived cells (CDC) resulted in positive effects, but this was the first time its effects in the aging process were tested. This is different from the tests performed last month at the Albert Einstein College of Medicine, where the hypothalamus region of the brain was discovered to be a key part of aging in mice.

Cedars-Sinai researchers instead took CDC cells from newborn mice and injected it into the hearts of older mice, while another group of older mice were injected with saline. Blood, echocardiographic, haemodynamic and treadmill stress tests were performed on all mice after injections, with the older groups tested 1 month later.

The mice given the Cardiosphere-derived cells saw a number of benefits compared to their saline counterparts. They had improved heart functionality, were able to exercise 20 percent longer, regrew hair at a faster rate, and had longer heart cell telomeres. This is important because telomeres are compounds found at the ends of chromosomes whose shortening is directly correlated to the aging process.

The way the cells work to reverse aging is fascinating, said Cedars-Sinai Heart Institute Director and Lead Researcher Eduardo Marbn, MD, PhD. They secrete tiny vesicles that are chock-full of signaling molecules such as RNA and proteins. The vesicles from young cells appear to contain all the needed instructions to turn back the clock.

Tests on ratshave shown that CDCs have shown cardiac and systemic rejuvenation on the aging process, but there is much work to do before the anti-aging treatment is tested on people, let alone over the table. Lilian Griorian-Shamagian, MD, PhD, who was co-primary researcher on the study, notes that its still unclear if the cells actually extend the lifespan of the rats, rather than simply providing a new heart in an old body. Its also unknown if CDCs need to be taken from younger hearts in order to be effective. If any CDCs, regardless of their origin, can be used, it could lead to a new round of tests comparing the effects of CDCs from the young to the CDCs from the old or middle-aged.

If stem cells were used for medical purposes, they couldhelp those suffering from heart failure, or the Duchenne muscular dystrophy Marbn and his team are hoping to treat. Beyond that, it could lessen the number of deaths caused by heart disease, which is currently responsible for over 610,000 deaths a year.

See the original post:
New Study Reveals Stem Cells from Young Hearts May Help Reverse the Aging Process - Futurism

U.S. DOD to Start New Trial with Pluristem’s PLX-R18 Cell Therapy … – Genetic Engineering & Biotechnology News

The U.S. Department of Defenses (DOD) Armed Forces Radiobiology Research Institute (AFRRI) is to undertake a pilot study in nonhuman primates (NHP) evaluating Pluristem Therapeutics PLX-R18 as a treatment for acute radiation syndrome (ARS) prior to and within the first 24 hours of radiation exposure. The AFRRI is part of the Uniformed Services University of Health Sciences (USUHS).

Pluristems PLX-R18 is an off-the-shelf placental expanded (PLX) cell therapy product generated from placenta-derived mesenchymal-like adherent stromal cells. The cells are designed to release a combination of therapeutic proteins to help treat bone marrow that has been damaged due to ARS, or as a result of cancer, cancer therapy, or immune-mediated bone marrow failure.

Last month, Pluristem reported positive data from an ongoing Phase II-equivalent NHP trial carried out by the National Institute of Allergy and Infectious Diseases (NIAID), which also investigated PLX-R18 cells as a treatment for ARS. The results confirmed that therapy increased survival rates in irradiated NHP animals.

The NIAID study is evaluating PLX-R18 administration 24 hours after radiation exposure. The prospective AFRRI study will evaluate therapy given prior to or within the first 24 hours of radiation exposure, which Pluristem points out is a timeframe that will be more relevant to the needs of the U.S. armed forces. Data from the two parallel studies will, in addition, provide a broader understanding of the potential therapeutic effects of PLX-R18 used as a countermeasure for ARS.

The new trial will also be carried out in accordance with FDAs Animal Rule pathway, which is followed when human efficacy trials are not feasible, in this case due to the ethics of exposing humans to nuclear radiation. Product approval via the Animal Rule pathway can be granted following large animal efficacy studies and human safety data.

We are pleased to see increased interest from U.S. governmental agencies in our PLX-R18 cell therapy, noted Zami Aberman, chairman and co-CEO of Pluristem. In view of the therapeutic effects of our product and the current geopolitical situation, governments can potentially shield their citizens from the dire health effects arising from exposure to nuclear radiation, saving many lives in the process, which is our ultimate goal.

Pluristems first PLX product, PLX-PAD, is designed for treating tissues damaged by ischemia, trauma, or inflammation, by secreting therapeutic proteins that trigger tissue repair, reduce inflammation, and modulate the immune system. The product is undergoing an international Phase III study for treating critical limb ischemia. The study, which will enroll 250 patients, is supported by an $8 million grant from the European Unions Horizon 2020 program. PLX-PAD is also undergoing Phase II development for treating intermittent claudication and is separately being evaluated for additional orthopedic indications, pulmonary arterial hypertension, and pre-eclampsia.

Pluristem has separately been granted FDA clearance to start a Phase I clinical trial evaluating PLX-R18 in patients with incomplete bone marrow recovery following hematopoietic cell transplantation.

Read more here:
U.S. DOD to Start New Trial with Pluristem's PLX-R18 Cell Therapy ... - Genetic Engineering & Biotechnology News

New treatment for deadly blood cancers expected to be approved soon – STLtoday.com

Cancer doctors in St. Louis are ready to use a new therapy using a patients own blood to fight their disease.

The therapy, called CAR-T, for chimeric antigen receptor T-cell, involves removing immune cells from the blood, reprogramming them genetically to find and destroy cancer cells and then returning the immune cells to the patient. So far, the therapy has been tested on patients with hard-to-treat advanced blood cancers such as leukemia, lymphoma and myeloma that kill more than 58,000 Americans a year.

In one small study sponsored by Novartis Pharmaceuticals, 52 of 63 pediatric and young adult patients with relapsed acute lymphoblastic leukemia went into remission after undergoing CAR-T therapy. The 11 other patients died, seven from the cancer and four from side effects of the treatment.

Acute lymphoblastic leukemia, the most common childhood cancer, can be effectively treated with chemotherapy, but survival rates drop below 30 percent if the patient relapses. Candidates for CAR-T therapy include an estimated 600 children each year who relapse or do not respond to traditional chemotherapy.

At least 16 of the 20 people who have received CAR-T therapy for leukemia or lymphoma through clinical trials at Washington Universitys Siteman Cancer Center have seen their cancers disappear after treatment.

Ive never seen anything in cancer history with that kind of response, said Dr. Armin Ghobadi, an assistant professor in oncology at Washington University. These are the basically bad, incurable, deadly, unstoppable cancers and patients usually die quickly when we dont give them this treatment.

If approved as expected by the Food and Drug Administration, CAR-T therapy could be available locally within a year. Currently no patients at St. Louis Childrens Hospital qualify for the therapy, but patients are expected to come from neighboring states, said Dr. Robert Hayashi, director of hematology/oncology at the hospital.

This advancement is significant and has already demonstrated that it can be an effective form of therapy, Hayashi said. The ability of being able to show a clear success opens the door in terms of what other cancers can benefit from this exact same strategy.

So far the therapy has shown the most effectiveness in cancers of the blood. Another small trial in China involved 33 out of 35 patients experiencing remission from relapsing multiple myeloma, a plasma cancer, after receiving CAR-T therapy.

For decades, scientists have tried to corral the bodys immune system to fight cancer the way it attacks harmful bacteria or viruses. The immune system has a harder time recognizing cancer cells, allowing them to grow. Re-engineering immune cells to fight cancer cells is like turning on the cars headlights at night, Ghobadi said.

A main challenge with CAR-T therapy is the length of time it can take to reprogram the patients blood cells up to three weeks. Researchers are studying ways to reduce the time frame, including engineering universal CAR-T cells derived from donor blood or umbilical cord blood.

CAR-T therapy is expected to cost up to $500,000 for a one-time treatment. Scientists at Washington University are working to engineer the cells in-house, which could lower the price.

The side effects of the treatment can be severe as the immune system is amplified to fight cancer. A complication called cytokine release syndrome can cause life-threatening reactions including brain swelling. In early studies, one-third to one-half of patients treated with CAR-T therapy developed the syndrome. Because patients will need to be closely monitored, drug companies will limit the treatments availability to a few dozen cancer centers nationwide, including Siteman.

Marie Miceli, 64, was one of the first to be treated with CAR-T cell therapy in a trial at Siteman after several rounds of chemotherapy and a stem cell replacement failed to knock out non-Hodgkin lymphoma.

A year later, Miceli is in remission and just celebrated the birth of her fourth grandchild. Miceli, a real estate agent and branch manager at Berkshire Hathaway in St. Louis, said she was blessed to receive the experimental treatment.

You have to trust those doctors and have faith, she said.

See original here:
New treatment for deadly blood cancers expected to be approved soon - STLtoday.com

Letter: Response to ‘Disappointed by Republicans’ – The Herald-News

To the Editor:

This is in response to Renee Klugmans Aug. 9 letter Disappointed by Republicans. I think Democrats, not Republicans, lost their soul.

Democrats are now the party of baby butchers, socialists, anti-freedom of speech, illegal immigration, anti-traditional family, and pro-sexual perversion.

Republican free-market policies raise everyones standard of living while Democrats socialism leads to more poverty and loss of freedom. Everyone agrees with having a safety net for those overtaken by adversity. But welfare as a way of life is inappropriate and harmful, perpetuating poverty and dependency.

The history of racism belongs to Democrats. The goal of the KKK was overthrow of Republican state governments in the South. The emancipation proclamation was favored by Republicans and opposed by Democrats.The 1964 Civil Rights Act was approved by 80 percent of Republicans and only 60 percent of Democrats.

Voter IDs cost little or nothing and keep no one from voting. People opposed to voter integrity want voter fraud.

Evangelicals voted for Trump as the lesser of two evils. Trump is appointing conservative judges to uphold the Constitution protecting freedom of religion.

I have degrees in physics and nuclear engineering, and an MBA. I like college and science.

The problem is many colleges today indoctrinate the students in Marxist and anti-American ideology while suppressing conservative and Christian speech.

They promote a lot of bad science like evolution, man-made climate change, and use of embryonic stem cells while squelching opposing facts. True science should be open to questioning and alternative ideas.

Please note the Social Security Trust Fund has zero real money because of lying liberals in both parties.

I am disappointed in the Democrats and establishment Republican politicians like Paul Ryan and Mitch McConnell. Trump was voted in to drain the swamp and the swamp creatures are fighting it.

Robert C. Lemke

Joliet

Link:
Letter: Response to 'Disappointed by Republicans' - The Herald-News